annual cash & cash equivalents:
$942.84M+$187.72M(+24.86%)Summary
- As of today (July 31, 2025), BMRN annual cash & cash equivalents is $942.84 million, with the most recent change of +$187.72 million (+24.86%) on December 31, 2024.
- During the last 3 years, BMRN annual cash & cash equivalents has risen by +$355.57 million (+60.54%).
- BMRN annual cash & cash equivalents is now at all-time high.
Performance
BMRN Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$1.05B+$105.96M(+11.24%)Summary
- As of today (July 31, 2025), BMRN quarterly cash & cash equivalents is $1.05 billion, with the most recent change of +$105.96 million (+11.24%) on March 31, 2025.
- Over the past year, BMRN quarterly cash & cash equivalents has increased by +$301.81 million (+40.40%).
- BMRN quarterly cash & cash equivalents is now at all-time high.
Performance
BMRN quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
BMRN Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +24.9% | +40.4% |
| 3 y3 years | +60.5% | +73.2% |
| 5 y5 years | +115.5% | +120.0% |
BMRN Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +60.5% | at high | +80.8% |
| 5 y | 5-year | at high | +115.5% | at high | +80.8% |
| alltime | all time | at high | +9930.2% | at high | >+9999.0% |
BMRN Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $1.05B(+11.2%) |
| Dec 2024 | $942.84M(+24.9%) | $942.84M(+39.6%) |
| Sep 2024 | - | $675.45M(-30.5%) |
| Jun 2024 | - | $972.15M(+30.1%) |
| Mar 2024 | - | $747.00M(-1.1%) |
| Dec 2023 | $755.13M(+4.2%) | $755.13M(-3.9%) |
| Sep 2023 | - | $785.41M(+13.1%) |
| Jun 2023 | - | $694.38M(+19.7%) |
| Mar 2023 | - | $580.07M(-19.9%) |
| Dec 2022 | $724.53M(+23.4%) | $724.53M(-4.9%) |
| Sep 2022 | - | $761.51M(+22.9%) |
| Jun 2022 | - | $619.80M(+2.4%) |
| Mar 2022 | - | $605.44M(+3.1%) |
| Dec 2021 | $587.28M(-9.5%) | $587.28M(-4.8%) |
| Sep 2021 | - | $617.14M(-3.8%) |
| Jun 2021 | - | $641.53M(-3.9%) |
| Mar 2021 | - | $667.31M(+2.8%) |
| Dec 2020 | $649.16M(+48.4%) | $649.16M(-36.1%) |
| Sep 2020 | - | $1.02B(+24.0%) |
| Jun 2020 | - | $818.90M(+71.8%) |
| Mar 2020 | - | $476.63M(+9.0%) |
| Dec 2019 | $437.45M(-11.4%) | $437.45M(+3.4%) |
| Sep 2019 | - | $423.22M(+37.6%) |
| Jun 2019 | - | $307.58M(-15.6%) |
| Mar 2019 | - | $364.37M(-26.2%) |
| Dec 2018 | $493.98M(-17.4%) | $493.98M(-44.0%) |
| Sep 2018 | - | $882.18M(+106.4%) |
| Jun 2018 | - | $427.41M(-9.8%) |
| Mar 2018 | - | $473.98M(-20.7%) |
| Dec 2017 | $598.03M(+46.5%) | $598.03M(+38.6%) |
| Sep 2017 | - | $431.40M(+21.6%) |
| Jun 2017 | - | $354.86M(+1.9%) |
| Mar 2017 | - | $348.23M(-14.7%) |
| Dec 2016 | $408.33M(+2.8%) | $408.33M(-42.3%) |
| Sep 2016 | - | $707.35M(+131.2%) |
| Jun 2016 | - | $305.97M(+13.1%) |
| Mar 2016 | - | $270.45M(-31.9%) |
| Dec 2015 | $397.04M(-54.6%) | $397.04M(+5.5%) |
| Sep 2015 | - | $376.35M(-14.6%) |
| Jun 2015 | - | $440.66M(-51.1%) |
| Mar 2015 | - | $900.57M(+2.9%) |
| Dec 2014 | $875.49M(+53.9%) | $875.49M(+120.0%) |
| Sep 2014 | - | $398.00M(-31.9%) |
| Jun 2014 | - | $584.72M(-8.6%) |
| Mar 2014 | - | $639.78M(+12.5%) |
| Dec 2013 | $568.78M(+215.1%) | $568.78M(+213.3%) |
| Sep 2013 | - | $181.56M(+3.5%) |
| Jun 2013 | - | $175.44M(+13.6%) |
| Mar 2013 | - | $154.38M(-14.5%) |
| Dec 2012 | $180.53M(+290.1%) | $180.53M(-0.4%) |
| Sep 2012 | - | $181.33M(+2.0%) |
| Jun 2012 | - | $177.76M(+115.2%) |
| Mar 2012 | - | $82.59M(+78.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2011 | $46.27M(-47.5%) | $46.27M(-35.1%) |
| Sep 2011 | - | $71.25M(-36.9%) |
| Jun 2011 | - | $112.96M(+24.4%) |
| Mar 2011 | - | $90.78M(+3.1%) |
| Dec 2010 | $88.08M(-47.3%) | $88.08M(-30.9%) |
| Sep 2010 | - | $127.54M(+10.2%) |
| Jun 2010 | - | $115.78M(+6.3%) |
| Mar 2010 | - | $108.96M(-34.8%) |
| Dec 2009 | $167.17M(-25.0%) | $167.17M(-12.8%) |
| Sep 2009 | - | $191.78M(-4.1%) |
| Jun 2009 | - | $200.05M(-6.8%) |
| Mar 2009 | - | $214.58M(-3.7%) |
| Dec 2008 | $222.90M(-2.4%) | $222.90M(-17.8%) |
| Sep 2008 | - | $271.22M(+7.5%) |
| Jun 2008 | - | $252.21M(-21.2%) |
| Mar 2008 | - | $319.99M(+40.1%) |
| Dec 2007 | $228.34M(+156.1%) | $228.34M(-21.8%) |
| Sep 2007 | - | $291.82M(+42.3%) |
| Jun 2007 | - | $205.01M(+108.5%) |
| Mar 2007 | - | $98.33M(+10.3%) |
| Dec 2006 | $89.16M(+134.1%) | $89.16M(-53.5%) |
| Sep 2006 | - | $191.78M(-32.9%) |
| Jun 2006 | - | $285.99M(-16.3%) |
| Mar 2006 | - | $341.69M(+797.0%) |
| Dec 2005 | $38.09M(+191.2%) | $38.09M(-32.2%) |
| Sep 2005 | - | $56.21M(+228.5%) |
| Jun 2005 | - | $17.11M(+52.2%) |
| Mar 2005 | - | $11.25M(-14.0%) |
| Dec 2004 | $13.08M(-89.2%) | $13.08M(-62.6%) |
| Sep 2004 | - | $34.98M(-27.5%) |
| Jun 2004 | - | $48.25M(-49.8%) |
| Mar 2004 | - | $96.20M(-20.8%) |
| Dec 2003 | $121.41M(+260.9%) | $121.41M(-35.4%) |
| Sep 2003 | - | $187.98M(-15.2%) |
| Jun 2003 | - | $221.77M(+76.2%) |
| Mar 2003 | - | $125.83M(+274.1%) |
| Dec 2002 | $33.64M(+168.5%) | $33.64M(+3.8%) |
| Sep 2002 | - | $32.41M(+67.4%) |
| Jun 2002 | - | $19.36M(+6.4%) |
| Mar 2002 | - | $18.20M(+45.3%) |
| Dec 2001 | $12.53M(-24.2%) | $12.53M(+73.3%) |
| Sep 2001 | - | $7.23M(-61.9%) |
| Jun 2001 | - | $18.97M(-3.8%) |
| Mar 2001 | - | $19.72M(+19.3%) |
| Dec 2000 | $16.53M(-29.4%) | $16.53M(+2.7%) |
| Sep 2000 | - | $16.10M(+51.7%) |
| Jun 2000 | - | $10.61M(-73.9%) |
| Mar 2000 | - | $40.67M(+73.7%) |
| Dec 1999 | $23.41M(+149.1%) | $23.41M(-28.2%) |
| Sep 1999 | - | $32.60M(+89.5%) |
| Jun 1999 | - | $17.20M(+377.8%) |
| Mar 1999 | - | $3.60M |
| Dec 1998 | $9.40M | - |
FAQ
- What is BioMarin Pharmaceutical Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for BioMarin Pharmaceutical Inc.?
- What is BioMarin Pharmaceutical Inc. annual cash & cash equivalents year-on-year change?
- What is BioMarin Pharmaceutical Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for BioMarin Pharmaceutical Inc.?
- What is BioMarin Pharmaceutical Inc. quarterly cash & cash equivalents year-on-year change?
What is BioMarin Pharmaceutical Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of BMRN is $942.84M
What is the all time high annual cash & cash equivalents for BioMarin Pharmaceutical Inc.?
BioMarin Pharmaceutical Inc. all-time high annual cash & cash equivalents is $942.84M
What is BioMarin Pharmaceutical Inc. annual cash & cash equivalents year-on-year change?
Over the past year, BMRN annual cash & cash equivalents has changed by +$187.72M (+24.86%)
What is BioMarin Pharmaceutical Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of BMRN is $1.05B
What is the all time high quarterly cash & cash equivalents for BioMarin Pharmaceutical Inc.?
BioMarin Pharmaceutical Inc. all-time high quarterly cash & cash equivalents is $1.05B
What is BioMarin Pharmaceutical Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, BMRN quarterly cash & cash equivalents has changed by +$301.81M (+40.40%)